John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

The GMO Frontier: 3 Synthetic Biology Stocks for Your Must-Buy List

By John Blankenhorn, InvestorPlace Contributor

The industries of the future are already available for investing today. Don't get left behind as synthetic biology stocks build the future.

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases

By John Blankenhorn, InvestorPlace Contributor

Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.

The 3 Most Undervalued AI Chip Stocks to Buy Now: August 2023

By John Blankenhorn, InvestorPlace Contributor

Many AI chip stocks have soared to unprecedented heights in 2023. But here are 3 undervalued AI chip stocks you might have missed.

The Rise of AI: 3 ChatGPT Stocks You Shouldn’t Miss Out On

By John Blankenhorn, InvestorPlace Contributor

Investors can't invest in ChatGPT directly, but here are the three best AI stocks you can get in on and ride the wave.

3 Space Stocks You’ll Regret Not Buying Soon

By John Blankenhorn, InvestorPlace Contributor

The 21st century will be the time of space travel. Ride the rocket with these top space stocks, or you'll kick yourself for missing out.

Load More